Early pharmacokinetic (PK) studies provide valuable information about the penetration of a drug into the eye and its bioavailability in the target tissue, as well as how it is distributed through tissues of the eye. Data from this research are evaluated along with data from efficacy studies to guide future work.
For pilot pharmacokinetic studies, Iris Pharma’s experienced and skilled staff can administer a drug in few animals, and perform microdissection and analysis of each structure of the eye to determine the PK profile and preliminary PK parameters such as Tmax, Cmax, half-life and area under the curve (AUC), with either non-radioactive or radioactive detection.
As part of pilot pharmacokinetic studies, Iris Pharma can perform microdissection and sampling of each eye structure, including:
Iris Pharma is one of the only contract research organizations to have technicians trained to perform microsurgery to remove all of the delicate eye structures, and to offer routine bioanalytical testing in these structures.
To support pilot pharmacokinetic studies, Iris Pharma’s bioanalytical team develops and validates a simple and fast method for quantifying the drug in the biological matrix of the eye using mass spectrometry (RRLC-MS/MS), chromatography (HPLC coupled with different detectors), immunoanalysis (EIA, RIA, and ELISA), macro-autoradiography, and radioactivity (beta and gamma counters).